Berlin - Delayed Quote ? EUR Inventiva SA (6IV.BE) Follow Compare 2.5950 +0.0950 (+3.80%) As of 12:40 PM GMT+2. Market Open. Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for 6IV.BE 1D 5D 9.49% 1M 40.27% 3M 3.80% 6M -18.40% YTD -37.24% 1Y -21.60% 2Y -57.87% 5Y 25.97% All -68.35% Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: 6IV.BE View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Pfizer invests in molecular glue; Jazz, MeiraGTx shares rise on drug data BioPharma Dive ? 6 days ago Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants GlobeNewswire ? 6 days ago Inventiva secures up to $380m for MASH treatment lanifibranor Pharmaceutical Technology ? 6 days ago Why Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday? Benzinga ? 6 days ago Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report GlobeNewswire ? 7 days ago Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study GlobeNewswire ? 7 days ago Inventiva (IVA) Loses -17.66% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner Zacks ? 19 days ago Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results GlobeNewswire ? 25 days ago Inventiva Reports Preliminary 2024 First-Half Financial Information1 GlobeNewswire ? 2 months ago Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor GlobeNewswire ? 2 months ago Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux GlobeNewswire ? 3 months ago View More Related Tickers CYCCP Cyclacel Pharmaceuticals, Inc. 7.30 +5.80% ? ANRO Alto Neuroscience, Inc. 14.43 +1.12% ? APVO Aptevo Therapeutics Inc. 0.1985 +23.60% ? DRUG Bright Minds Biosciences Inc. 47.21 +117.56% ?
